NCT06084858Not yet recruiting
Effect of Changes in Dialysate Bicarbonate on Serum Calcification Propensity and Calciprotein Particles in Hemodialysis Patients
Effect of Dialysate Bicarbonate Prescription on Serum Calcification Propensity and Calciprotein Particles in Hemodialysis Patients
Prim. Priv. Doz. Dr. Daniel CejkaPhase 2ClinicalTrials.govother
Study focus
- Disease/Condition
- End Stage Renal Disease
- Drug/Device/Intervention
- Dialysate bicarbonate modification
- Study type
- Interventional
- Intervention type
- other
Sponsor & location
- Primary sponsor
- Prim. Priv. Doz. Dr. Daniel Cejka
- Funder
- Elisabethinen Hospital
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Dec 01, 2023
- End date
- Dec 01, 2024
- Enrollment
- 24 participants
Primary outcome
T50-Laboratory Test for measuring calcification
Summary
This is a single-center, prospective, proof-of-priciple, pilot study in 24 end-stage renal
 disease patients on chronic hemodiaysis.
ICD-10 classifications
Chronic kidney disease, stage 1Chronic kidney disease, stage 5Chronic kidney disease, stage 2Chronic kidney disease, stage 3Chronic kidney disease, stage 4
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06084858
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06084858 through Pure Global AI's free database. This Phase 2 trial is sponsored by Prim. Priv. Doz. Dr. Daniel Cejka and is currently Not yet recruiting. The study focuses on End Stage Renal Disease. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.